{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:01:14Z","timestamp":1789189274660,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":290,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872900"],"award-info":[{"award-number":["81872900"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803021"],"award-info":[{"award-number":["81803021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019T120855"],"award-info":[{"award-number":["2019T120855"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M650248"],"award-info":[{"award-number":["2019M650248"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Science and Technology Program","award":["2019YFH0123"],"award-info":[{"award-number":["2019YFH0123"]}]},{"name":"Sichuan Science and Technology Program","award":["2019YFH0124"],"award-info":[{"award-number":["2019YFH0124"]}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1074\/jbc.ra119.010732","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T16:45:11Z","timestamp":1571417111000},"page":"18099-18108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of \u03b2-tubulin explains KXO1's low clinical toxicity"],"prefix":"10.1016","volume":"294","author":[{"given":"Lu","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2398-4482","authenticated-orcid":false,"given":"Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.RA119.010732_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/1541-7786.MCR-16-0297-T","article-title":"Dual Src kinase\/pretubulin inhibitor, KX-01, sensitizes ER\u03b1-negative breast cancers to tamoxifen through ER\u03b1 reexpression","volume":"15","author":"Anbalagan","year":"2017","journal-title":"Mol. Cancer Res"},{"key":"10.1074\/jbc.RA119.010732_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4143\/crt.2016.168","article-title":"Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res. Treat"},{"key":"10.1074\/jbc.RA119.010732_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-011-1513-3","article-title":"KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor \u03b1 positive breast cancer","volume":"132","author":"Anbalagan","year":"2012","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1074\/jbc.RA119.010732_bib4","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-13-1305","article-title":"Targeting Src and tubulin in mucinous ovarian carcinoma","volume":"19","author":"Liu","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1074\/jbc.RA119.010732_bib5","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2\u2013391 and KX2\u2013361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.RA119.010732_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2\u2013391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1074\/jbc.RA119.010732_bib7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.bjc.6605917","article-title":"A phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours","volume":"103","author":"van Herpen","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1074\/jbc.RA119.010732_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10637-013-9929-8","article-title":"A phase I trial of KX2\u2013391, a novel non-ATP competitive substrate-pocket-directed SRC inhibitor, in patients with advanced malignancies","volume":"31","author":"Naing","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1074\/jbc.RA119.010732_bib9","first-page":"4983","article-title":"KXO1 (KX2\u2013391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo","volume":"68","author":"Yahao","year":"2008","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.RA119.010732_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","article-title":"Recent developments in tubulin polymerization inhibitors: an overview","volume":"87","author":"Kaur","year":"2014","journal-title":"Eur. J. Med. Chem"},{"key":"10.1074\/jbc.RA119.010732_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nmat3858","article-title":"Transformation of Taxol-stabilized microtubules into inverted tubulin tubules triggered by a tubulin conformation switch","volume":"13","author":"Ojeda-Lopez","year":"2014","journal-title":"Nat. Mater"},{"key":"10.1074\/jbc.RA119.010732_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature03566","article-title":"Structural basis for the regulation of tubulin by vinblastine","volume":"435","author":"Gigant","year":"2005","journal-title":"Nature"},{"key":"10.1074\/jbc.RA119.010732_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"key":"10.1074\/jbc.RA119.010732_bib14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/anie.201307749","article-title":"Structural basis of microtubule stabilization by laulimalide and peloruside A","volume":"53","author":"Prota","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl"},{"key":"10.1074\/jbc.RA119.010732_bib15","doi-asserted-by":"crossref","first-page":"13817","DOI":"10.1073\/pnas.1408124111","article-title":"A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs","volume":"111","author":"Prota","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.RA119.010732_bib16","doi-asserted-by":"crossref","first-page":"12103","DOI":"10.1038\/ncomms12103","article-title":"Pironetin reacts covalently with cysteine-316 of \u03b1-tubulin to destabilize microtubule","volume":"7","author":"Yang","year":"2016","journal-title":"Nat. Commun"},{"key":"10.1074\/jbc.RA119.010732_bib17","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.jmb.2016.06.023","article-title":"Pironetin binds covalently to \u03b1Cys316 and perturbs a major loop and helix of \u03b1-tubulin to inhibit microtubule formation","volume":"428","author":"Prota","year":"2016","journal-title":"J. Mol. Biol"},{"key":"10.1074\/jbc.RA119.010732_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2010","journal-title":"Clin. Trans. Oncol"},{"key":"10.1074\/jbc.RA119.010732_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000489983","article-title":"SKLB060 reversibly binds to colchicine site of tubulin and possesses efficacy in multidrug-resistant cell lines","volume":"47","author":"Yan","year":"2018","journal-title":"Cell. Physiol. Biochem"},{"key":"10.1074\/jbc.RA119.010732_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1074\/jbc.RA119.010732_bib21","doi-asserted-by":"crossref","first-page":"14544","DOI":"10.1021\/bi701412k","article-title":"Luminescence studies of perturbation of tryptophan residues of tubulin in the complexes of tubulin with colchicine and colchicine analogues","volume":"46","author":"Sardar","year":"2007","journal-title":"Biochemistry"},{"key":"10.1074\/jbc.RA119.010732_bib22","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1038\/ncomms9722","article-title":"The \u03b3-tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle","volume":"6","author":"Chinen","year":"2015","journal-title":"Nat. Commun"},{"key":"10.1074\/jbc.RA119.010732_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12575-010-9029-5","article-title":"Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site","volume":"12","author":"Fortin","year":"2010","journal-title":"Biol. Proced. Online"},{"key":"10.1074\/jbc.RA119.010732_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1230582","article-title":"Molecular mechanism of action of microtubule-stabilizing anticancer agents","volume":"339","author":"Prota","year":"2013","journal-title":"Science"},{"key":"10.1074\/jbc.RA119.010732_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/febs.13555","article-title":"Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery","volume":"283","author":"Wang","year":"2016","journal-title":"FEBS J"},{"key":"10.1074\/jbc.RA119.010732_bib26","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1158\/0008-5472.CAN-15-2525","article-title":"Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity","volume":"76","author":"Wozniak","year":"2016","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.RA119.010732_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.RA119.010732_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0014-5793(79)80985-0","article-title":"Colcemid and colchicine binding to tubulin. Similarity and dissimilarity","volume":"99","author":"Banerjee","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1074\/jbc.RA119.010732_bib29","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1074\/jbc.RA117.001658","article-title":"The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in \u03b2-tubulin","volume":"293","author":"Yang","year":"2018","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.RA119.010732_bib30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-015-2903-8","article-title":"Antimitotic drugs in the treatment of cancer","volume":"76","author":"van Vuuren","year":"2015","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1074\/jbc.RA119.010732_bib31","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/ERC-17-0120","article-title":"Fighting tubulin-targeting anticancer drug toxicity and resistance","volume":"24","author":"Visconti","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1074\/jbc.RA119.010732_bib32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: The integration of data reduction and structure solution\u2014from diffraction images to an initial model in minutes","volume":"62","author":"Minor","year":"2006","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA119.010732_bib33","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA119.010732_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA119.010732_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1074\/jbc.RA119.010732_bib36","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1038\/srep07697","article-title":"Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820306773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820306773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.RA119.010732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T07:55:13Z","timestamp":1639814113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820306773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":36,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0021925820306773"],"URL":"https:\/\/doi.org\/10.1074\/jbc.ra119.010732","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of \u03b2-tubulin explains KXO1's low clinical toxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.RA119.010732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Niu et al.","name":"copyright","label":"Copyright"}]}}